Trailing-twelve-month (TTM) revenue is $512.27 Million with a year-over-year growth of +8.04%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $134,224,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $139,163,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $114,493,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $124,395,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $512,275,000 |
Current P/S: $2,349,016,467 market capitalization ÷ $512,275,000 TTM revenue = 4.59x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:15:22.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $124.39M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:15:36.804Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20162016-12-31 · USD | FY20192019-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|---|---|---|---|
| ADMA BioManufacturing | N/A | $22M | N/A | N/A | N/A | N/A |
| ADMA BioManufacturing Segment | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|
| International | N/A | $16M | N/A |
| Non-US | N/A | N/A | $6M |
| United States | $146M | $410M | N/A |
| UNITED STATES | N/A | N/A |
$512.27M
$512.27 Million
+8.04%
vs. $474.15M a year ago (TTM)
+54.55%
5 Year compound annual growth rate
1 Year
+8.04%
3 Year
+35.01%
5 Year
+54.55%
10 Year
+50.22%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $510.17M | +$83.72M | +19.63% |
| 2024 | $426.45M | +$168.24M | +65.15% |
| 2023 | $258.21M | +$104.14M | +67.59% |
| 2022 | $154.08M | +$73.14M | +90.36% |
| 2021 | $80.94M | +$38.72M | +91.72% |
| 2020 |
TTM Growth
+8.04%
3-Year CAGR
+35.01%
5-Year CAGR
+54.55%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T19:15:36.804Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| $161M |
| $416M |
| Corporate | $142,834 | $142,834 | N/A | N/A | N/A | N/A |
|---|
| License Revenue | N/A | N/A | $142,834 | $142,834 | N/A | N/A |
|---|
| Plasma Collection Centers | $11M | $7M | N/A | N/A | N/A | N/A |
|---|
| Plasma Collection Centers Segment | N/A | N/A | N/A | N/A | $8M | $11M |
|---|
| Product Revenue | N/A | N/A | $81M | $154M | N/A | N/A |
|---|
| Research And Development | $0 | N/A | N/A | N/A | N/A | N/A |
|---|
| $504M |
| $42.22M |
| +$12.87M |
| +43.85% |
| 2019 | $29.35M | +$12.36M | +72.79% |
| 2018 | $16.99M | ($5.78M) | (25.37%) |
| 2017 | $22.76M | +$12.10M | +113.49% |
| 2016 | $10.66M | +$3.48M | +48.53% |
